文献速递基础与转化研究临床试验与 GCP

18F-MPG PET成像用于无创评估非小细胞肺癌EGFR突变状态

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
PubMed 文献 · Sci Transl Med · 2018-01-01

研究开发了靶向EGFR激活突变的高特异性PET示踪剂18F-MPG,在NSCLC动物模型和75例患者中评估其无创定量EGFR突变状态的可行性。动物模型显示18F-MPG摄取与EGFR激活突变显著相关(R2=0.9050),临床中PET/CT与组织活检一致率达84.29%。SUVmax≥2.23的患者对EGFR-TKI应答率更高(81.58% vs 6.06%),中位无进展生存期更长(348天 vs 183天)。

要点

  • 18F-MPG PET/CT可无创定量NSCLC患者EGFR激活突变状态,与组织活检一致率84.29%。
  • SUVmax≥2.23提示对EGFR-TKI应答更好、无进展生存期更长。
  • 该技术有望用于筛选EGFR-TKI敏感患者并监测疗效。

核心结论

  • 18F-MPG PET/CT能精准定量NSCLC患者EGFR激活突变状态,是无创识别EGFR-TKI敏感患者和监测疗效的有前景策略。

研究设计与样本

  • 研究纳入NSCLC动物模型及75例原发和转移性NSCLC患者,评估18F-MPG PET成像与EGFR激活突变状态的相关性及临床一致性。

主要发现

  • NSCLC动物模型中18F-MPG摄取与EGFR激活突变状态显著相关(R2=0.9050)。
  • 75例NSCLC患者中,18F-MPG PET/CT检测EGFR激活与组织活检的一致率达84.29%。
  • SUVmax≥2.23组对比<2.23组,EGFR-TKI应答率更高(81.58% vs 6.06%),中位无进展生存期更长(348天 vs 183天)。

关键数值与推荐

  • 18F-MPG PET/CT与组织活检检测EGFR激活的一致率为84.29%(n=75)。
  • SUVmax≥2.23 vs <2.23:EGFR-TKI应答率81.58% vs 6.06%,中位PFS 348天 vs 183天。

临床怎么用

  • 可利用18F-MPG PET/CT无创评估NSCLC患者EGFR激活突变状态,辅助筛选EGFR-TKI敏感人群。
  • SUVmax≥2.23可作为提示EGFR-TKI应答和预后的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) mutation status over time challenge the design of effective EGFR tyrosine kinase inhibitor (TKI) treatment strategies for non-small cell lung cancer (NSCLC). Therefore, there is an urgent need to develop techniques for comprehensive tumor EGFR profiling in real time, particularly in lung cancer precision medicine trials. We report a positron emission tomography (PET) tracer, N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-18F-fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG), with high specificity to activating EGFR mutant kinase. We evaluate the feasibility of using 18F-MPG PET for noninvasive imaging and quantification of EGFR-activating mutation status in preclinical models of NSCLC and in patients with primary and metastatic NSCLC tumors. 18F-MPG PET in NSCLC animal models showed a significant correlation (R2 = 0.9050) between 18F-MPG uptake and activating EGFR mutation status. In clinical studies with NSCLC patients (n = 75), the concordance between the detection of EGFR activation by 18F-MPG PET/computed tomography (CT) and tissue biopsy reached 84.29%. There was a greater response to EGFR-TKIs (81.58% versus 6.06%) and longer median progression-free survival (348 days versus 183 days) in NSCLC patients when 18F-MPG PET/CT SUVmax (maximum standard uptake value) was ≥2.23 versus <2.23. Our study demonstrates that 18F-MPG PET/CT is a powerful method for precise quantification of EGFR-activating mutation status in NSCLC patients, and it is a promising strategy for noninvasively identifying patients sensitive to EGFR-TKIs and for monitoring the efficacy of EGFR-TKI therapy.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Sun X, Xiao Z, Chen G, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018. PMID: 29515002. doi:10.1126/scitranslmed.aan8840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。